secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2023-02-27T23:59:59+00:00
Accession:  0001485003-23-000068
Event type: regulatory
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Sesen Bio gets Nasdaq exception to complete Carisma merger by March 10; delisting risk if not compliant
--------------------------------------------------------------------------------

- Nasdaq Panel granted exception from $1.00 bid price rule to complete merger with Carisma by March 10, 2023.
- Special meeting of stockholders on March 2, 2023 to approve merger and reverse stock split.
- If compliance not demonstrated by March 10, common stock will be delisted unless further exception granted.
- Company must demonstrate compliance with all initial listing requirements upon closing of merger.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000148500323000068/0001485003-23-000068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000148500323000068/sesn-20230224.htm
  HTML page:      https://secwatch.observer/filing/0001485003-23-000068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer